They also provide an overview of treatment options available and a brief indication of what the future holds GLP-1 receptor agonists: Optimising nutritional outcomes in primary care GLP-1 receptor agonists: Optimising nutritional outcomes in primary care Dietitian Sarah MacAvoy explains that while new weight-loss medications show exciting potential, they also put patients at risk of nutritional deficiencies, and dietitian support is essential Kia ora and welcome to New Zealand Doctor Rata Aotearoa Not a subscriber
Blood sugar control: Up to 80% of people with PMOS have insulin resistance, which can affect both diabetes risk and pelvic floor function
Tirzepatide and Testosterone Most of the research on GLP-1 medications and testosterone has focused on semaglutide, but tirzepatide (which acts on both GLP-1 and GIP receptors) is producing even larger weight loss results in clinical trials
The FDA actively monitors these shortages, but delays and access issues remain common
Insulin syringes work well for BPC-157 injection due to their small needle gauge (typically 29-31 gauge) and precise volume markings
Despite recent progress in the development of xCT inhibitors, effective treatment interventions focusing on metabolic vulnerabilities remain unmet